Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
4.280
+0.090 (2.15%)
At close: Apr 28, 2026, 4:00 PM EDT
4.180
-0.100 (-2.34%)
After-hours: Apr 28, 2026, 5:34 PM EDT
CPIX Revenue
In the year 2025, Cumberland Pharmaceuticals had annual revenue of $44.52M with 17.57% growth. Cumberland Pharmaceuticals had revenue of $13.68M in the quarter ending December 31, 2025, with 31.08% growth.
Revenue (ttm)
$44.52M
Revenue Growth
+17.57%
P/S Ratio
1.44
Revenue / Employee
$478,725
Employees
93
Market Cap
64.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.52M | 6.65M | 17.57% |
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Assertio Holdings | 118.71M |
| InterCure | 72.16M |
| Rockwell Medical | 69.26M |
| Journey Medical | 61.86M |
| BGM Group | 25.10M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| BioXcel Therapeutics | 642.00K |
CPIX News
- 1 hour ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE - PRNewsWire
- 1 day ago - RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 5 days ago - Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex - PRNewsWire
- 6 days ago - RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 - PRNewsWire
- 12 days ago - CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE - PRNewsWire
- 6 weeks ago - Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting - PRNewsWire
- 7 weeks ago - CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH - PRNewsWire
- 2 months ago - Cumberland Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts